NCT03627052View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 20, 2018

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Moderate to Severe Ulcerative Colitis
Interventions
DRUG

Itacitinib

In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.

DRUG

Placebo

Placebo administered orally twice daily in the double-blind period.

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT03627052 - A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter